Advancing Science & Animal Welfare Together | Nov. 2022 Issue

New Appointment to IIVS Board of Directors

IIVS is pleased to announce the appointment of Amanda Ulrey to our Board of Directors. As a 20-year veteran at IIVS, Mandy is currently Vice President of Business Operations and where she is primarily responsible for instituting quality management systems and regulatory compliance throughout the organization, as well as administering IIVS’ business-to-business certification in Good In Vitro Method Practices (GIVIMP). She has been a Registered Quality Assurance Professional in Good Laboratory Practices since 2005 and has presented, trained, and authored white papers on the topics of the application of GLPs to in vitro studies, the OECD GIVIMP guidance document, the importance of supplier qualification programs, and IT compliance and computer software validation. We are pleased to add Amanda’s experience and input to our board.

BASF Laboratory Awarded GIVIMP Certification

IIVS pleased to announce the first laboratory worldwide to receive GIVIMP certification: The BASF Experimental Toxicology and Ecology Laboratory in Ludwigshafen, Germany. Dr. Susanne Kolle, who is responsible for GIVIMP implementation at BASF remarked: “The GIVIMP certification provides a third-party testimony to our commitment to quality. Additionally, we will be seeking adherence to these principles by test method developers and laboratories who wish to work with us.”

The full press release is available on our website

Dr. Robert Landsiedel accepts GIVIMP certification on behalf of BASF’s Experimental Toxicology and Ecology Laboratory. Presented by Amanda Ulrey, Vice President, IIVS

IIVS recently presented a poster on this topic: Good In Vitro Method Practices (GIVIMP) Certification: A Roadmap for Implementation and Harmonization at the EUROTOX/ICT conference.

New Publication

Dr. Holger Behrsing, Director of Respiratory Services at IIVS, recently co-authored a journal article entitled “Use of New Approach Methodologies (NAMs) to meet regulatory requirements for the assessment of tobacco and other nicotine-containing products.”

On October 3rd, IIVS celebrated its 25th anniversary. Thank you to all of our clients and contributors for helping us to achieve our mission to increase the use and acceptance of in vitro methods!

IIVS wishes all of our clients, supporters and contributors an enjoyable holiday season! Please note that IIVS will be closed and unable to receive test materials during the following dates:

November 24th-27th

December 24th-January 2nd


Additionally, IIVS will be unable to perform studies requiring human reconstructed epidermal or epithelial tissues during these weeks (including the week of January 2nd) as well. Please contact for further information or with questions.

Connect With Us

Facebook  Twitter  LinkedIn  YouTube